Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.72 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468287 | 0.91 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4472400 | 0.87 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4460652 | 0.86 | MAPK14 (0.79) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13712660 | 0.85 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4473049 | 0.85 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4461338 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4463927 | 0.84 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4460506 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4469461 | 0.83 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4464560 | 0.82 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE-GMBH (DE) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | IL2, TPMT, IFNG | MAPK14 3841/4885MAPK13 3803/4885MAPK12 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.